DrugPatentWatch Database Preview
PF PRISM CV Company Profile
What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?
PF PRISM CV has seventeen approved drugs.
There are forty-four US patents protecting PF PRISM CV drugs.
There are nine hundred and ninety-eight patent family members on PF PRISM CV drugs in sixty-eight countries and ninety-six supplementary protection certificates in seventeen countries.
Summary for PF PRISM CV
| International Patents: | 998 |
| US Patents: | 44 |
| Tradenames: | 13 |
| Ingredients: | 12 |
| NDAs: | 17 |
Drugs and US Patents for PF PRISM CV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | 7,767,678 | Start Trial | Y | Y | Start Trial | ||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-002 | Aug 26, 2011 | RX | Yes | Yes | 7,858,643 | Start Trial | Y | Y | Start Trial | ||
| Pf Prism Cv | CHANTIX | varenicline tartrate | TABLET;ORAL | 021928-001 | May 10, 2006 | RX | Yes | No | Start Trial | Start Trial | |||||
| Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-001 | Nov 6, 2012 | RX | Yes | No | Start Trial | Start Trial | |||||
| Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-001 | May 24, 2002 | AB | RX | Yes | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PF PRISM CV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-004 | Jan 25, 2010 | 5,100,899*PED | Start Trial |
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | 6,002,008 | Start Trial |
| Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | 5,529,990 | Start Trial |
| Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-004 | Jan 25, 2010 | 5,212,155*PED | Start Trial |
| Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-001 | Aug 25, 2000 | 5,989,591*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PF PRISM CV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2015-05-08 |
| ➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2018-10-15 |
| ➤ Subscribe | Oral Solution | 20 mg/mL | ➤ Subscribe | 2010-05-19 |
| ➤ Subscribe | Tablets | 1 mg and 5 mg | ➤ Subscribe | 2018-02-23 |
| ➤ Subscribe | Tablets | 50 mg and 200 mg | ➤ Subscribe | 2008-04-14 |
| ➤ Subscribe | For Injection | 50 mg per vial | ➤ Subscribe | 2009-06-15 |
| ➤ Subscribe | Tablets | 1 mg and 2 mg | ➤ Subscribe | 2009-12-17 |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Extended-release Tablets | 50 mg and 100 mg | ➤ Subscribe | 2012-02-29 |
| ➤ Subscribe | Tablets | 100mg and 500mg | ➤ Subscribe | 2016-09-06 |
| ➤ Subscribe | Capsules | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | ➤ Subscribe | 2008-12-30 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-10 |
| ➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2008-09-12 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2010-10-08 |
| ➤ Subscribe | Injection | 25 mg/mL, 1.8 mL vial | ➤ Subscribe | 2011-05-25 |
| ➤ Subscribe | Tablets | 0.5 mg | ➤ Subscribe | 2010-08-25 |
International Patents for PF PRISM CV Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Germany | 69330949 | Start Trial |
| Mexico | PA05001013 | Start Trial |
| Japan | H07508288 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2005053650 | Start Trial |
| Bulgaria | 106908 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PF PRISM CV Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1218348 | 5/2013 | Austria | Start Trial | PRODUCT NAME: AXITINIB; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903 |
| 1235830 | C01235830/01 | Switzerland | Start Trial | PRODUCT NAME: TOFACITINIB; REGISTRATION NO/DATE: SWISSMEDIC 62630 12.07.2013 |
| 1786785 | 449 | Finland | Start Trial | |
| 1786785 | 167 5008-2013 | Slovakia | Start Trial | PRODUCT NAME: KRIZOTINIB; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023 |
| 1786785 | C01786785/01 | Switzerland | Start Trial | PRODUCT NAME: CRIZOTINIB; REGISTRATION NO/DATE: SWISSMEDIC 62131 05.03.2012 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
